Log in

NYSE:BMYBristol-Myers Squibb Stock Price, Forecast & News

$57.43
-0.68 (-1.17 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$57.16
Now: $57.43
$58.09
50-Day Range
$55.10
MA: $58.95
$61.43
52-Week Range
$42.48
Now: $57.43
$68.34
Volume8.77 million shs
Average Volume15.60 million shs
Market Capitalization$129.95 billion
P/E Ratio70.90
Dividend Yield3.10%
Beta0.73
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Read More
Bristol-Myers Squibb logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 4.2Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.16 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP11012210
Phone212-546-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.15 billion
Cash Flow$4.34 per share
Book Value$23.20 per share

Profitability

Net Income$3.44 billion

Miscellaneous

Employees30,000
Outstanding Shares2,262,690,000
Market Cap$129.95 billion
Next Earnings Date8/6/2020 (Confirmed)
OptionableOptionable

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

How has Bristol-Myers Squibb's stock been impacted by COVID-19 (Coronavirus)?

Bristol-Myers Squibb's stock was trading at $56.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BMY stock has increased by 1.6% and is now trading at $57.43. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Bristol-Myers Squibb?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bristol-Myers Squibb.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Bristol-Myers Squibb.

How can I listen to Bristol-Myers Squibb's earnings call?

Bristol-Myers Squibb will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) posted its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.49 by $0.23. The biopharmaceutical company had revenue of $10.78 billion for the quarter, compared to the consensus estimate of $10.04 billion. Bristol-Myers Squibb had a net margin of 3.08% and a return on equity of 30.06%. Bristol-Myers Squibb's revenue for the quarter was up 82.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.10 earnings per share. View Bristol-Myers Squibb's earnings history.

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb declared a quarterly dividend on Thursday, June 11th. Shareholders of record on Monday, July 6th will be given a dividend of $0.45 per share on Monday, August 3rd. This represents a $1.80 annualized dividend and a yield of 3.13%. The ex-dividend date of this dividend is Thursday, July 2nd. View Bristol-Myers Squibb's dividend history.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb issued an update on its FY21 earnings guidance on Thursday, May, 7th. The company provided EPS guidance of $7.15-7.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.39.

What price target have analysts set for BMY?

14 brokerages have issued 12 month price objectives for Bristol-Myers Squibb's stock. Their forecasts range from $50.00 to $88.00. On average, they expect Bristol-Myers Squibb's share price to reach $68.17 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price. View analysts' price targets for Bristol-Myers Squibb.

Has Bristol-Myers Squibb been receiving favorable news coverage?

Media stories about BMY stock have been trending neutral on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bristol-Myers Squibb earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Bristol-Myers Squibb.

Who are some of Bristol-Myers Squibb's key competitors?

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Bank of America (BAC), NVIDIA (NVDA), Intel (INTC), Johnson & Johnson (JNJ), Cisco Systems (CSCO) and CVS Health (CVS).

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the following people:
  • Dr. Giovanni Caforio, Chairman & CEO (Age 54)
  • Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)
  • Dr. Thomas J. Lynch Jr., Exec. VP & Chief Scientific Officer (Age 58)
  • Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 58)
  • Mr. Paul von Autenried, Sr. VP & Chief Information Officer (Age 57)

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Hexavest Inc. (0.04%), DNB Asset Management AS (0.03%), Manning & Napier Group LLC (0.03%), State of Alaska Department of Revenue (0.03%), Cullinan Associates Inc. (0.01%) and Private Asset Management Inc. (0.01%). Company insiders that own Bristol-Myers Squibb stock include Adam Dubow, Dinesh C Paliwal, John E Elicker, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini and Theodore R Samuels II. View institutional ownership trends for Bristol-Myers Squibb.

Which institutional investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Oak Asset Management LLC, HNP Capital LLC, Fulton Bank N. A., M&R Capital Management Inc., Global Trust Asset Management LLC, Corrado Advisors LLC, and Santori & Peters Inc.. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Adam Dubow, John E Elicker, and Louis S Schmukler. View insider buying and selling activity for Bristol-Myers Squibb.

Which institutional investors are buying Bristol-Myers Squibb stock?

BMY stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, State of Alaska Department of Revenue, Canandaigua National Corp, Thomasville National Bank, Platte River Wealth Advisors LLC, Manning & Napier Group LLC, Xcel Wealth Management LLC, and OmniStar Financial Group Inc.. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini, and Theodore R Samuels II. View insider buying and selling activity for Bristol-Myers Squibb.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $57.43.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $129.95 billion and generates $26.15 billion in revenue each year. The biopharmaceutical company earns $3.44 billion in net income (profit) each year or $4.69 on an earnings per share basis. Bristol-Myers Squibb employs 30,000 workers across the globe.

What is Bristol-Myers Squibb's official website?

The official website for Bristol-Myers Squibb is www.bms.com.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.